TLR4 and neoplasm: Beyond its cytotoxic effects, Paclitaxel has shown immune-modulatory properties, specifically reprogramming TAMs from a tumor-promoting M2 phenotype to an antitumor M1 phenotype through TLR4 (Toll-like receptor 4) signaling.